ProCE Banner Activity

REFLECTIONS: Phase III Study of Rituximab Biosimilar PF-05280586 vs Reference Rituximab in Untreated CD20+ Follicular Lymphoma

Slideset Download
Conference Coverage
The rituximab biosimilar candidate PF-05280586 showed therapeutic equivalence and a similar safety profile vs reference rituximab-EU in previously untreated patients with CD20-positive low tumor burden follicular lymphoma.

Released: December 06, 2018

Expiration: December 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology